Whole-body biodistribution and brain PET imaging with [18F]AV-45, a novel amyloid imaging agent - a pilot study

Nuclear Medicine and Biology

Volumn 37, Issue 4, 2010, Pages 497-508

  Lin, Kun Ju ^a,b   Hsu, Wen Chuin ^a   Hsiao, Ing Tsung ^a,b   Wey, Shiaw Pyng ^a,b   Jin, Lee Way ^d   Skovronsky, Daniel ^e   Wai, Yau Yau ^a   Chang, Hsiu Ping ^a   Lo, Chuan Wei ^a   Yao, Cheng Hsiang ^a   Yen, Tzu Chen ^a   Kung, Mei Ping ^a,c  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e AVID RADIOPHARMACEUTICALS   (United States)

Author keywords

amyloid; Brain PET; Dosimetry; Whole body biodistribution

Indexed keywords

4 [2 [6 [2 [2 (2 FLUOROETHOXY)ETHOXY]ETHOXY]PYRIDIN 3 YL]VINYL] N METHYLBENZENAMINE F 18; AMYLOID; AV 45; TRACER; UNCLASSIFIED DRUG;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; AUTOPSY; AUTORADIOGRAPHY; BINDING AFFINITY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DOSE RESPONSE; DOSIMETRY; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG SPECIFICITY; DRUG STRUCTURE; DRUG TARGETING; DRUG UPTAKE; FLUORESCENCE ANALYSIS; GALLBLADDER; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IN VITRO STUDY; MOLECULAR IMAGING; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PILOT STUDY; POSITRON EMISSION TOMOGRAPHY; STRUCTURE ACTIVITY RELATION;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID; ANILINE COMPOUNDS; BRAIN; CASE-CONTROL STUDIES; ETHYLENE GLYCOLS; FEMALE; FLUORESCENT DYES; FLUORINE RADIOISOTOPES; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; POSITRON-EMISSION TOMOGRAPHY; RADIOMETRY; THIAZOLES;

EID: 77952552594     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2010.02.003     Document Type: Article

References (36)

1. Selkoe D.J. The origins of Alzheimer disease: A is for amyloid. JAMA 2000, 283:1615-1617.
2. Ginsberg S.D., Schmidt M.L., Crino P.B., Eberwine J.H., Lee V.M.Y., Trojanowski J.Q. Molecular pathology of Alzheimer's disease and related disorders. Cerebral cortex: neurodegenerative and age-related changes in structure and function of cerebral cortex 1999, 603-654. Kluwer Academic/Plenum Publishers, New York. A. Peters, J.H. Morrison (Eds.).
3. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
4. Selkoe D.J. Imaging Alzheimer's amyloid. Nat Biotechnol 2000, 18:823-824.
5. Mathis C.A., Klunk W.E., Price J.C., DeKosky S.T. Imaging technology for neurodegenerative diseases: progress toward detection of specific pathologies. Arch Neurol 2005, 62:196-200.
6. Klunk W.E., Engler H., Nordberg A., Wang Y., Blomqvist G., Holt D.P., et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004, 55:306-319.
7. Henriksen G., Yousefi B.H., Drzezga A., Wester H.J. Development and evaluation of compounds for imaging of beta-amyloid plaque by means of positron emission tomography. Eur J Nucl Med Mol Imaging 2008, 35(Suppl 1):S75-S81.
8. Nordberg A. Amyloid plaque imaging in vivo: current achievement and future prospects. Eur J Nucl Med Mol Imaging 2008, 35(Suppl 1):S46-S50.
9. 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem 2003, 46:2740-2754.
10. 11C]SB-13 PET. Am J Geriatr Psychiatry 2004, 12:584-595.
11. 11C-labeled stilbene derivatives as Abeta-aggregate-specific PET imaging agents for Alzheimer's disease. Nucl Med Biol 2003, 30:565-571.
12. Kudo Y., Okamura N., Furumoto S., Tashiro M., Furukawa K., Maruyama M., et al. 2-(2-[2-Dimethylaminothiazol-5-yl]ethenyl)-6-(2-[fluoro]ethoxy)benzoxazole: a novel PET agent for in vivo detection of dense amyloid plaques in Alzheimer's disease patients. J Nucl Med 2007, 48:553-561.
13. 11C]MeS-IMPY, a candidate radioligand for beta-amyloid plaques. Nucl Med Biol 2007, 34:681-689.
14. Shoghi-Jadid K., Barrio J.R., Kepe V., Wu H.M., Small G.W., Phelps M.E., et al. Imaging beta-amyloid fibrils in Alzheimer's disease: a critical analysis through simulation of amyloid fibril polymerization. Nucl Med Biol 2005, 32:337-351.
15. Small G.W. Diagnostic issues in dementia: neuroimaging as a surrogate marker of disease. J Geriatr Psychiatry Neurol 2006, 19:180-185.
16. 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol 2008, 7:129-135.
17. 18F-GE067: a radioligand for in vivo brain amyloid imaging. J Nucl Med 2009, 50:818-822.
18. Forsberg A., Engler H., Almkvist O., Blomquist G., Hagman G., Wall A., et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging 2008, 29:1456-1465.
19. Lopresti B.J., Klunk W.E., Mathis C.A., Hoge J.A., Ziolko S.K., Lu X., et al. Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med 2005, 46:1959-1972.
20. 18F-labeled amyloid-imaging agents in Alzheimer's disease patients and healthy elderly controls. J Nucl Med 2008, 49:390-398.
21. Choi S.R., Skovronsky D., Hefti F., Carpenter A., Golding G., Zhuang Z.P., et al. F-18 AV-45 (florpiramine F-18): a PET imaging agent for mapping beta-amyloid plaques in the brain. J Nucl Med 2009, 50(Suppl 2):1190.
22. 18F-AV-45: a PET agent for Aβ plaques in the brain. J Nucl Med 2009, 50:1887-1894.
23. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984, 34:939-944.
24. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 1994, American Psychiatric Association, Washington, DC. 4th ed.
25. 18F-labeled biphenylalkyne as a positron emission tomography imaging agent for beta-amyloid plaques. Nucl Med Biol 2009, 36:411-417.
26. Morris J.C., Ernesto C., Schafer K., Coats M., Leon S., Sano M., et al. Clinical dementia rating training and reliability in multicenter studies: the Alzheimer's Disease Cooperative Study experience. Neurology 1997, 48:1508-1510.
27. Stabin M.G., Sparks R.B., Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 2005, 46:1023-1027.
28. 123I]ADAM - a serotonin transporter radiotracer in healthy human subjects. Nucl Med Biol 2006, 33:193-202.
29. Loevinger R., Budinger T., Watson E. MIRD primer for absorbed dose calculations 1988, Society of Nuclear Medicine, New York.
30. Valentin J. Basic anatomical and physiological data for use in radiological protection: reference values. ICRP Publication 89 2001, 167-185. Pergamon Press, Oxford (UK).
31. International Commission on Radiological Protection 1990 Recommendations of the International Commission on Radiological Protection 1991, ICRP Publication 60.
32. Adler L., Wolodzko J., Stabin M., McNelis T., Gammage L., Joshi A. Radiation dosimetry of F18-AV-45 measured by PET/CT in humans. J Nucl Med 2008, 49(Suppl 1):283P.
33. 18F-BAY94-9172. J Nucl Med 2009, 50:309-315.
34. 18F]AV-45. J Nucl Med 2008, 49(Suppl 1):214P.
35. 11C]PiB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 2006, 67:446-452.
36. McNamee R.L., Yee S.H., Price J.C., Klunk W.E., Rosario B., Weissfeld L., et al. Consideration of optimal time window for Pittsburgh compound B PET summed uptake measurements. J Nucl Med 2009, 50:348-355.